Please Wait
Applying Filters...
menu
    • menu
    munit-sa-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-04-14

    Virtual Booth

    Contact Supplier

    Menu

    Roxadustat

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,782Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FibroGen publishes Ph 1 study results of FG-3246 in Prostate Cancer
    FibroGen publishes Ph 1 study results of FG-3246 in Prostate Cancer

    28 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/28/3051262/33525/en/FibroGen-Announces-Publication-of-Results-from-Phase-1-Monotherapy-Study-of-FG-3246-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer-in-the-Journal-of-Clinical-Onco.html

    GLOBENEWSWIRE
    28 Mar 2025
    Share Share
    FibroGen to Present at H.C. Wainwright 26th Annual Global Conference
    FibroGen to Present at H.C. Wainwright 26th Annual Global Conference

    03 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/03/2940091/33525/en/FibroGen-to-Present-at-the-H-C-Wainwright-26th-Annual-Global-Investment-Conference.html

    GLOBENEWSWIRE
    03 Sep 2024
    Share Share
    AstraZeneca finally drops roxadustat US rights
    AstraZeneca finally drops roxadustat US rights

    28 Feb 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/astrazeneca-finally-drops-roxadustat-us-rights-after-fda-rejection-trial-failure

    FIERCE PHARMA
    28 Feb 2024
    Share Share
    FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States
    FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States

    26 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/26/2835490/33525/en/FibroGen-Regains-All-Rights-to-Roxadustat-from-AstraZeneca-in-the-United-States-and-Other-AstraZeneca-Territories-Except-China-and-South-Korea.html

    GLOBENEWSWIRE
    26 Feb 2024
    Share Share
    FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat
    FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat

    09 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/09/2793446/33525/en/FibroGen-Presents-Data-from-Phase-3-MATTERHORN-Trial-of-Roxadustat-in-Patients-with-Anemia-of-Lower-Risk-Transfusion-Dependent-Myelodysplastic-Syndromes-at-American-Society-of-Hema.html

    GLOBENEWSWIRE
    09 Dec 2023
    Share Share
    FibroGen faces more trouble in clinic as DMD drug fails phase 3
    FibroGen faces more trouble in clinic as DMD drug fails phase 3

    08 Jun 2023

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/fibrogen-faces-more-trouble-clinic-dmd-drug-fails-phase-3-trial

    FIERCE BIOTECH
    08 Jun 2023
    Share Share